ATE236255T1 - Impfstoff gegen den hepatitis e-virus und verfahren - Google Patents

Impfstoff gegen den hepatitis e-virus und verfahren

Info

Publication number
ATE236255T1
ATE236255T1 AT93911555T AT93911555T ATE236255T1 AT E236255 T1 ATE236255 T1 AT E236255T1 AT 93911555 T AT93911555 T AT 93911555T AT 93911555 T AT93911555 T AT 93911555T AT E236255 T1 ATE236255 T1 AT E236255T1
Authority
AT
Austria
Prior art keywords
hev
effective
antibody
infection
composition
Prior art date
Application number
AT93911555T
Other languages
English (en)
Inventor
Gregory R Reyes
Daniel W Bradley
Jr-Shin Twu
Michael A Purdy
Albert W Tam
Krzysztof Z Krawczynski
Patrice O Yarbough
Original Assignee
Genelabs Tech Inc
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc, Us Gov Health & Human Serv filed Critical Genelabs Tech Inc
Application granted granted Critical
Publication of ATE236255T1 publication Critical patent/ATE236255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93911555T 1992-01-17 1993-01-15 Impfstoff gegen den hepatitis e-virus und verfahren ATE236255T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82233592A 1992-01-17 1992-01-17
US07/870,985 US6455492B1 (en) 1988-06-17 1992-04-20 Hepatitis E virus vaccine and method
PCT/US1993/000475 WO1993014208A2 (en) 1992-01-17 1993-01-19 Hepatitis e virus vaccine and method

Publications (1)

Publication Number Publication Date
ATE236255T1 true ATE236255T1 (de) 2003-04-15

Family

ID=27124631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911555T ATE236255T1 (de) 1992-01-17 1993-01-15 Impfstoff gegen den hepatitis e-virus und verfahren

Country Status (9)

Country Link
US (3) US6455492B1 (de)
EP (1) EP0623169B1 (de)
JP (2) JP3746291B2 (de)
AT (1) ATE236255T1 (de)
CA (1) CA2125701A1 (de)
DE (1) DE69332820T2 (de)
DK (1) DK0623169T3 (de)
ES (1) ES2196008T3 (de)
WO (1) WO1993014208A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789559A (en) * 1988-06-17 1998-08-04 Genelabs Technologies, Inc. DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent
US5686239A (en) * 1988-06-17 1997-11-11 Genelabs Technologies, Inc. Hepatitis E virus peptides and methods
US6455492B1 (en) * 1988-06-17 2002-09-24 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US6214970B1 (en) 1988-06-17 2001-04-10 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US6291641B1 (en) 1988-06-17 2001-09-18 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US6787145B1 (en) 1992-09-18 2004-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
ES2336282T3 (es) * 1992-09-18 2010-04-09 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Proteinas recombinantes de una cepa paquistani de hepatitis e y su utilizacion en metodos de diagnostico y vacunas.
US6207416B1 (en) 1992-09-18 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
US5563032A (en) * 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus
US5736315A (en) * 1992-10-21 1998-04-07 National Institute Of Health Methods and compositions for detecting anti-hepatitis E virus activity
AU694139B2 (en) * 1993-09-24 1998-07-16 Macfarlane Burnet Centre For Medical Research Limited, The Immunoreactive antigens of hepatitis E virus
US5830636A (en) * 1993-12-22 1998-11-03 Abbott Laboratories HEV orf-2 monoclonal antibodies and methods for using same
EP0736088A1 (de) * 1993-12-22 1996-10-09 Abbott Laboratories Monoklonale antikörper gegen das hepatitis-e-virus und verfahren für ihre verwendung
CA2179609A1 (en) * 1993-12-22 1995-06-29 Deborah A. Paul Monoclonal antibodies against hev orf-2 and methods for using same
US6054567A (en) * 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
US6458562B1 (en) 1998-04-09 2002-10-01 The United States Of America As Represented By The Secretary Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
CA2283538A1 (en) * 1999-09-30 2001-03-30 Mun Hon Ng New hev antigenic peptide and methods
US7005130B2 (en) 2001-01-05 2006-02-28 Virginia Tech Intellectual Properties, Inc. Avian hepatitis E virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis E
US20030220475A1 (en) * 2001-04-03 2003-11-27 Fields Howard A. Neutralizing immunogenic hev polypepetides
US6614586B2 (en) * 2001-07-30 2003-09-02 Dorsal Networks, Inc. Methods and systems for high performance, wide bandwidth optical communication systems using Raman amplification
US7309589B2 (en) * 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
RU2501568C1 (ru) * 2012-04-27 2013-12-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита е у животных
RU2501809C1 (ru) * 2012-04-27 2013-12-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантного капсидного белка вируса гепатита е и рекомбинантная вакцина для профилактики вирусного гепатита е
RU2493249C1 (ru) * 2012-04-27 2013-09-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей hansenula polymorpha - продуцент капсидного белка вируса гепатита е

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218099A (en) * 1986-04-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Post-transfusion, non-A, non-B hepatitis virus polynucleotides
FR2597606B1 (fr) * 1986-04-16 1989-10-06 Pasteur Institut Nouveau reactif pour la detection d'hepatites virales non a non b et procede de diagnostic de telles hepatites par voie immunoenzymatique
US5686239A (en) * 1988-06-17 1997-11-11 Genelabs Technologies, Inc. Hepatitis E virus peptides and methods
US5741490A (en) * 1988-06-17 1998-04-21 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
WO1989012641A1 (en) * 1988-06-17 1989-12-28 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US5885768A (en) * 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
US6455492B1 (en) * 1988-06-17 2002-09-24 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US5202430A (en) * 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
DE69133599D1 (de) * 1990-04-05 2008-08-21 Genelabs Tech Inc Enterisch übertragendes non-a/non-b-hepatitis-virus agens und charakteristische epitope von selbigem
JPH04200388A (ja) * 1990-11-29 1992-07-21 Chemo Sero Therapeut Res Inst 流行性非ａ非ｂ型肝炎ウイルス抗原ペプチドおよびこれをコードする核酸断片
ES2336282T3 (es) * 1992-09-18 2010-04-09 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Proteinas recombinantes de una cepa paquistani de hepatitis e y su utilizacion en metodos de diagnostico y vacunas.

Also Published As

Publication number Publication date
US6455492B1 (en) 2002-09-24
EP0623169A1 (de) 1994-11-09
DE69332820T2 (de) 2004-01-29
JPH08509201A (ja) 1996-10-01
JP3746291B2 (ja) 2006-02-15
EP0623169B1 (de) 2003-04-02
US5770689A (en) 1998-06-23
ES2196008T3 (es) 2003-12-16
JP2006036795A (ja) 2006-02-09
WO1993014208A3 (en) 1993-10-14
WO1993014208A2 (en) 1993-07-22
DE69332820D1 (de) 2003-05-08
CA2125701A1 (en) 1993-07-22
US20030143241A1 (en) 2003-07-31
DK0623169T3 (da) 2003-07-21

Similar Documents

Publication Publication Date Title
ATE236255T1 (de) Impfstoff gegen den hepatitis e-virus und verfahren
ATE454901T1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
LU91393I2 (fr) "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
DE69111801D1 (de) Vakzin gegen hepatitis b.
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
LU91324I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)-gardasil/silgard
DE69334299D1 (de) Rekombinante proteine eines pakistani stammes von hepatitis e-virus sowie ihre verwendung in diagnostischen verfahren und als vakzine
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
MX9603182A (es) Vacuna de hepatitis b.
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
KR970706300A (ko) E형 간염 파키스탄형 균주의 재조합 단백질 및 이를 이용한 진단방법과 백신(recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines)
Grose et al. Immunogenic glycoproteins of laboratory and vaccine strains of varicella-zoster virus
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
DK0551275T3 (da) Non-A non-B sekvenser
NO933897D0 (no) Hbv-overflateproteiner med redusert vertskarbohydrat
DE69104012T2 (de) Rekombiniebares Hepatitis-Delta-Antigen, Verfahren zu seiner Reinigung und Verwendung.
DE69331796D1 (de) Kernantigenprotein des Hepatitis C-Virus, sowie diagnostisches Verfahren und Satz von Reagenzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0623169

Country of ref document: EP

REN Ceased due to non-payment of the annual fee